UBXN2A and neoplasm: The inhibited tumor growth observed in weeks 10 and 12 in VTD (0.1 mg/kg) treated UBXN2A (+/−) mice shows that elevation of UBXN2A by VTD can overcome pre-existing low UBXN2A levels and actively slow tumor growth.